These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 29793946)
21. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). Jerusalem G; Mariani G; Ciruelos EM; Martin M; Tjan-Heijnen VC; Neven P; Gavila JG; Michelotti A; Montemurro F; Generali D; Simoncini E; Lang I; Mardiak J; Naume B; Camozzi M; Lorizzo K; Bianchetti S; Conte P Ann Oncol; 2016 Sep; 27(9):1719-25. PubMed ID: 27358383 [TBL] [Abstract][Full Text] [Related]
22. Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer. Tamura K; Kodaira M; Shimizu C; Yonemori K; Yunokawa M; Shimomura A; Kobayashi T; Nakano K; Tomomatsu J; Ito Y; Tanaka J; Kuriki H; Gu Z; Takahashi S Cancer Sci; 2018 May; 109(5):1592-1601. PubMed ID: 29500843 [TBL] [Abstract][Full Text] [Related]
23. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer. Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934 [TBL] [Abstract][Full Text] [Related]
24. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733 [TBL] [Abstract][Full Text] [Related]
25. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Mayer IA; Prat A; Egle D; Blau S; Fidalgo JAP; Gnant M; Fasching PA; Colleoni M; Wolff AC; Winer EP; Singer CF; Hurvitz S; Estévez LG; van Dam PA; Kümmel S; Mundhenke C; Holmes F; Babbar N; Charbonnier L; Diaz-Padilla I; Vogl FD; Sellami D; Arteaga CL Clin Cancer Res; 2019 May; 25(10):2975-2987. PubMed ID: 30723140 [TBL] [Abstract][Full Text] [Related]
26. VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results. Lindeman GJ; Fernando TM; Bowen R; Jerzak KJ; Song X; Decker T; Boyle F; McCune S; Armstrong A; Shannon C; Bertelli G; Chang CW; Desai R; Gupta K; Wilson TR; Flechais A; Bardia A Clin Cancer Res; 2022 Aug; 28(15):3256-3267. PubMed ID: 35583555 [TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029 [TBL] [Abstract][Full Text] [Related]
28. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. Slamon DJ; Neven P; Chia S; Fasching PA; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Esteva FJ; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Pivot X; Vidam G; Wang Y; Rodriguez Lorenc K; Miller M; Taran T; Jerusalem G J Clin Oncol; 2018 Aug; 36(24):2465-2472. PubMed ID: 29860922 [TBL] [Abstract][Full Text] [Related]
29. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994 [TBL] [Abstract][Full Text] [Related]
30. Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression. Welt A; Wiesweg M; Theurer S; Abenhardt W; Groschek M; Müller L; Schröder J; Tewes M; Chiabudini M; Potthoff K; Bankfalvi A; Marschner N; Schuler M; Breitenbücher F Cancer Med; 2020 Jul; 9(13):4527-4539. PubMed ID: 32352244 [TBL] [Abstract][Full Text] [Related]
31. ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. Chen JW; Jacot W; Cortés J; Krop IE; Dent S; Harbeck N; De Laurentiis M; Diéras V; Im YH; Stout TJ; Schimmoller F; Savage HM; Hutchinson KE; Wilson TR Mol Oncol; 2023 Oct; 17(10):2000-2016. PubMed ID: 36892268 [TBL] [Abstract][Full Text] [Related]
32. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410 [TBL] [Abstract][Full Text] [Related]
33. Phase II Study of Taselisib in Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919 [TBL] [Abstract][Full Text] [Related]
34. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640 [TBL] [Abstract][Full Text] [Related]
35. Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer. Hoste G; Slembrouck L; Jongen L; Punie K; Matton T; Vander Borght S; Vanden Bempt I; Menten J; Wildiers H; Floris G; Arteaga C; Neven P Clin Drug Investig; 2018 Nov; 38(11):1071-1075. PubMed ID: 30187361 [TBL] [Abstract][Full Text] [Related]
36. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR Lehmann BD; Abramson VG; Sanders ME; Mayer EL; Haddad TC; Nanda R; Van Poznak C; Storniolo AM; Nangia JR; Gonzalez-Ericsson PI; Sanchez V; Johnson KN; Abramson RG; Chen SC; Shyr Y; Arteaga CL; Wolff AC; Pietenpol JA; Clin Cancer Res; 2020 May; 26(9):2111-2123. PubMed ID: 31822498 [TBL] [Abstract][Full Text] [Related]
37. Patient-Reported Outcomes in Patients With Ciruelos EM; Rugo HS; Mayer IA; Levy C; Forget F; Delgado Mingorance JI; Safra T; Masuda N; Park YH; Juric D; Conte P; Campone M; Loibl S; Iwata H; Zhou X; Park J; Ridolfi A; Lorenzo I; André F J Clin Oncol; 2021 Jun; 39(18):2005-2015. PubMed ID: 33780274 [TBL] [Abstract][Full Text] [Related]
40. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]